Sunday, November 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· March 6, 2026

Sezzle and Sea have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
Sezzle and Sea have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – March 6, 2026 – Zacks Equity Research shares Sezzle SEZL as the Bull of the Day and Sea Ltd…
Opening lines of the source · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Zacks Consensus Estimate for American Express' 2026 earnings is pegged at $17.50 per share, implying a 13.8% jump from the year-ago period

    80% confidence
  • Adjusted EBITDA at least flat year over year for 2026

    80% confidence
  • Sezzle is a Zack Rank #1 (Strong Buy)

    80% confidence
  • Garena is guiding to double digit bookings growth in 2026

    80% confidence
  • Projecting revenue growth of 25 to 30% year over year for FY26

    80% confidence
  • Guiding to $4.70 in EPS versus $4.33 expected for FY26

    80% confidence
  • B. Riley Securities reiterated their 'Buy' rating on Sezzle

    80% confidence
  • Management emphasized a focus on higher lifetime value subscribers and proprietary shopping features, positioning the company to sustain earnings quality into 2026

    80% confidence
  • Sea Ltd. is a Zacks Rank #5 (Strong Sell)

    80% confidence
  • Guiding to roughly 25% GMV growth at Shopee for 2026

    80% confidence
  • Guiding to $170 million in adjusted net income, up 31% year over year on a per share basis for FY26

    80% confidence

Data points we hold from this source

Visa Inc. · payments volume yoy growth8 percent

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Sources reconciled: no open conflicts right now.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,959
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,959 facts checked against source5,585 source documents archived
Query this data → isubstrate.com